Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of a Human Extracellular Matrix Implanted in the Bone Interstices & the Cartilage Defect Following Arthroscopic Microfracture Surgery in the Knee,in Comparison to Microfracture Surgery Alone

Next Previous
Trial Profile

A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of a Human Extracellular Matrix Implanted in the Bone Interstices & the Cartilage Defect Following Arthroscopic Microfracture Surgery in the Knee,in Comparison to Microfracture Surgery Alone

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 23 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HST 003 (Primary)
  • Indications Cartilage disorders; Postoperative complications
  • Focus Therapeutic Use
  • Acronyms hECM;HST003
  • Sponsors Histogen [CEASED]

Most Recent Events

  • 17 Jan 2023 Status changed from recruiting to discontinued.
  • 11 Aug 2022 According to a Histogen media release, despite adding three additional clinical sites in the first quarter of 2022, study continue to experience recruitment challenges due to both the specific nature of the study inclusion criteria and the impact of COVID-19 on the elective surgery environment. The company is evaluating the overall feasibility of trial, including implementing protocol modifications, adding more sites, expect to complete our feasibility evaluation in the fourth quarter of 2022.
  • 09 Nov 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top